Efficacy of combined supplementation of vitamins A/D/K1/K2 on the growth and development of preterm infants: A randomized controlled trial.

Nutr Clin PractMay 13, 2026 (epub)
Clinical ResearchPediatricsEndocrinology

Yuanyuan Ding, Huiyan Du

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of combined supplementation of vitamins A and K2 on the growth and skeletal development of 86 preterm infants. The intervention group, receiving additional vitamins A and K2, showed significant improvements in bone mineral density and height standard deviation score after 12 months compared to the control group.

Key findings

  • The intervention group had higher lumbar spine and femur BMD after 12 months.
  • Greater height standard deviation score (HtSDS) was observed in the intervention group.
  • Serum levels of vitamins A, D, K1, K2, and 25-OH-D were significantly higher in the intervention group.
  • No significant difference in adverse reactions was noted between the two groups.

Why it matters

The findings suggest that additional supplementation of vitamins A and K2 can enhance skeletal development and micronutrient status in preterm infants, which is crucial for their growth and long-term health outcomes.

Source

PubMed · PMID 42125969

Published in Nutr Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.